Cargando…

Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2

Pomalidomide (Pom) is an immunomodulatory drug that has efficacy against Kaposi’s sarcoma, a tumor caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). Pom also induces direct cytotoxicity in primary effusion lymphoma (PEL), a B-cell malignancy caused by KSHV, in part through downregulation of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shrestha, Prabha, Davis, David A., Jaeger, Hannah K., Stream, Alexandra, Aisabor, Ashley I., Yarchoan, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817053/ https://www.ncbi.nlm.nih.gov/pubmed/33411730 http://dx.doi.org/10.1371/journal.ppat.1009091

Ejemplares similares

Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas
por: Jaeger, Hannah K., et al.
Publicado: (2023)

Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells
por: Davis, David A., et al.
Publicado: (2018)

Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide
por: Davis, David A., et al.
Publicado: (2017)

Hypoxia-inducible factor-1 alpha as a therapeutic target for primary effusion lymphoma
por: Shrestha, Prabha, et al.
Publicado: (2017)

Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease
por: Shrestha, Prabha, et al.
Publicado: (2023)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021)

Population Pharmacokinetics of Pomalidomide
por: Li, Yan, et al.
Publicado: (2015)

Pomalidomide-induced hypothyroidism
por: Ali, Sulaiman Haji, et al.
Publicado: (2017)

Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300
por: Davis, David A., et al.
Publicado: (2021)

Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide
por: Gutowska, Anna, et al.
Publicado: (2022)

Pomalidomide for the Treatment of Multiple Myeloma
por: Clark, Stephen M., et al.
Publicado: (2014)

Regulation of Retroviral and SARS-CoV-2 Protease Dimerization and Activity through Reversible Oxidation
por: Davis, David A., et al.
Publicado: (2022)

Regulation of the Dimerization and Activity of SARS-CoV-2 Main Protease through Reversible Glutathionylation of Cysteine 300
por: Davis, David A., et al.
Publicado: (2021)

Spotlight on pomalidomide: could less be more?
por: Zander, T, et al.
Publicado: (2017)

Current Concepts in Primary Effusion Lymphoma and Other Effusion-Based Lymphomas
por: Kim, Yoonjung, et al.
Publicado: (2014)

Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma
por: Burbelo, Peter D, et al.
Publicado: (2010)

Profile of pomalidomide and its potential in the treatment of myelofibrosis
por: Gowin, Krisstina L, et al.
Publicado: (2015)

Pomalidomide Reduces Ischemic Brain Injury in Rodents
por: Tsai, Yan-Rou, et al.
Publicado: (2019)

Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma
por: Modi, Dipenkumar, et al.
Publicado: (2015)

CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules
por: Wu, Yiquan, et al.
Publicado: (2022)

Primary Effusion Lymphoma Presenting As Parapneumonic Pleural Effusion
por: Gujarathi, Rahul, et al.
Publicado: (2022)

PB2337: SHORT-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB COMBINED WITH POMALIDOMIDE IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM LYMPHOMA
por: Zhang, Zhipeng, et al.
Publicado: (2023)

Upregulation of ICAM-1 in diabetic rats after transient forebrain ischemia and reperfusion injury
por: Jing, Li, et al.
Publicado: (2014)

Diagnostic significance of adenosine deaminase in pleural effusate for primary effusion lymphoma–like lymphoma
por: Nakako, Soichiro, et al.
Publicado: (2020)

New drugs in multiple myeloma – role of carfilzomib and pomalidomide
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
por: Chanan-Khan, A A, et al.
Publicado: (2013)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Pomalidomide-induced lung injury: A case report
por: Vivien, Alexandre, et al.
Publicado: (2023)

Pleural effusion in Burkitt's lymphoma.
por: Aderele, W. I., et al.
Publicado: (1975)

Indolent primary effusion lymphoma
por: Nagrale, Vidya, et al.
Publicado: (2020)

Pomalidomide Shows Significant Therapeutic Activity against CNS Lymphoma with a Major Impact on the Tumor Microenvironment in Murine Models
por: Li, Zhimin, et al.
Publicado: (2013)

Characterization of the function of intercellular adhesion molecule (ICAM)-3 and comparison with ICAM-1 and ICAM-2 in immune responses
Publicado: (1994)

Kaposi sarcoma herpesvirus viral load as a biomarker for leptomeningeal involvement by primary effusion lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2022)

Primary Effusion Lymphoma without an Effusion: A Rare Case of Solid Extracavitary Variant of Primary Effusion Lymphoma in an HIV-Positive Patient
por: Hashmi, Hamza, et al.
Publicado: (2018)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2017)

Pomalidomide-induced changes in the pancreatic tumor microenvironment and potential for therapy
por: Storz, Peter
Publicado: (2019)

PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates
por: Shimizu, Nobuyuki, et al.
Publicado: (2021)

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
por: Young, Mary H., et al.
Publicado: (2021)

Rapid synthesis of pomalidomide-conjugates for the development of protein degrader libraries
por: Brownsey, Duncan K., et al.
Publicado: (2021)

Multi-omics investigation of the resistance mechanisms of pomalidomide in multiple myeloma
por: Zhuang, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ahj3vtdfkk9as2d659l8ph5ntt